Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $81.11, for a total value of $1,622,200.00. Following the completion of the transaction, the chief executive officer directly owned 1,192,987 shares of the company’s stock, valued at $96,763,175.57. This represents a 1.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, December 10th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.38, for a total transaction of $1,507,600.00.
• On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.01, for a total transaction of $3,000,400.00.
• On Thursday, November 13th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $63.01, for a total transaction of $1,260,200.00.

Apogee Therapeutics Price Performance

NASDAQ APGE opened at $80.77 on Friday. The stock has a market capitalization of $5.52 billion, a price-to-earnings ratio of -18.44 and a beta of 1.41. Apogee Therapeutics Inc. has a 1-year low of $26.20 and a 1-year high of $84.56. The business’s fifty day moving average price is $73.44 and its 200-day moving average price is $53.18.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. Equities research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

A number of large investors have recently modified their holdings of APGE. ANTIPODES PARTNERS Ltd raised its position in shares of Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after buying an additional 246 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Apogee Therapeutics by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock valued at $77,000 after acquiring an additional 272 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock valued at $33,000 after acquiring an additional 383 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Apogee Therapeutics by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after acquiring an additional 694 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Apogee Therapeutics by 34.7% during the second quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock worth $158,000 after purchasing an additional 941 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. BTIG Research set a $137.00 price objective on Apogee Therapeutics in a research note on Tuesday, January 6th. UBS Group raised Apogee Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Apogee Therapeutics in a report on Tuesday, January 6th. Finally, Mizuho initiated coverage on Apogee Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $105.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.27.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.